(CVS) CVS Health - Overview
Sector: Healthcare | Industry: Healthcare Plans | Exchange: NYSE (USA) | Market Cap: 122.349m USD | Total Return: 55.5% in 12m
Health Insurance, Pharmacy Benefits, Prescription Drugs, Retail Merchandise
Total Rating 63
Safety 74
Buy Signal 0.92
Healthcare Plans
Industry Rotation: +29.2
Industry Rotation: +29.2
Market Cap:
122B
Avg Turnover: 703M
Avg Turnover: 703M
Risk 3d forecast
Volatility35.5%
VaR 5th Pctl5.61%
VaR vs Median-5.14%
Reward TTM
Sharpe Ratio1.45
Rel. Str. IBD81.8
Rel. Str. Peer Group73.2
Character TTM
Beta0.433
Beta Downside0.641
Hurst Exponent0.365
Drawdowns 3y
Max DD43.98%
CAGR/Max DD0.34
CAGR/Mean DD1.15
EPS (Earnings per Share)
EPS CAGR: 1.84%
EPS Trend: -40.6%
EPS Trend: -40.6%
Last SUE: 0.98
Qual. Beats: 0
Qual. Beats: 0
Revenue
Rev. CAGR: 6.03%
Rev. Trend: 95.7%
Rev. Trend: 95.7%
Last SUE: 2.93
Qual. Beats: 1
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
Tailwind, Pullback 52w, Confidence, Garp
Description: CVS CVS Health
CVS Health Corporation is an integrated healthcare provider operating through three primary segments: Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness. The company provides a comprehensive suite of services including health insurance plans, pharmacy benefit management (PBM), and retail pharmacy operations. Historically, CVS transitioned from a traditional drugstore chain to a diversified healthcare entity, notably through its acquisition of Aetna and the expansion of its clinical service offerings.
The business model relies on vertical integration to capture value across the patient care continuum, from insurance underwriting to drug dispensing and primary care delivery. In the Health Care Services sector, this integration aims to lower overall medical costs by managing pharmacy spend and improving patient adherence through its vast retail footprint. The company serves a diverse client base ranging from individual consumers and employer groups to government entities like Medicare and Medicaid.
For a more granular look at the company’s financial health and valuation metrics, consider reviewing the detailed data available on ValueRay. CVS Health remains a central player in the U.S. healthcare infrastructure, leveraging its 1963 founding roots and Rhode Island headquarters to maintain its position as a leading provider of medical and pharmacy solutions.
- Medicare Advantage utilization rates and Star Ratings impact health benefits segment profitability
- Pharmacy Benefit Management regulatory scrutiny threatens traditional drug pricing and rebate models
- Vertical integration of primary care assets drives long-term medical cost ratio reduction
- Retail pharmacy margin compression persists due to declining reimbursement rates and competition
- High debt levels from recent acquisitions influence capital allocation and dividend growth
Piotroski VR‑10 (Strict)
2.5
| Net Income: 2.93b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 0.60 > 1.0 |
| NWC/Revenue: -2.84% < 20% (prev -4.16%; Δ 1.32% < -1%) |
| CFO/TA 0.04 > 3% & CFO 10.33b > Net Income 2.93b |
| Net Debt (68.80b) to EBITDA (11.13b): 6.18 < 3 |
| Current Ratio: 0.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.28b) vs 12m ago 1.19% < -2% |
| Gross Margin: 13.87% > 18% (prev 0.14%; Δ 1.37k% > 0.5%) |
| Asset Turnover: 160.4% > 50% (prev 148.3%; Δ 12.14% > 0%) |
| Interest Coverage Ratio: 2.11 > 6 (EBITDA TTM 11.13b / Interest Expense TTM 3.11b) |
Altman Z''
1.37
| A: -0.05 (Total Current Assets 74.82b - Total Current Liabilities 86.41b) / Total Assets 252.97b |
| B: 0.25 (Retained Earnings 63.28b / Total Assets 252.97b) |
| C: 0.03 (EBIT TTM 6.57b / Avg Total Assets 254.28b) |
| D: 0.65 (Book Value of Equity 114.16b / Total Liabilities 175.34b) |
| Altman-Z'' Score: 1.37 = BB |
Beneish M
-3.03
| DSRI: 0.96 (Receivables 40.99b/39.62b, Revenue 407.90b/378.96b) |
| GMI: 1.01 (GM 13.87% / 14.05%) |
| AQI: 0.99 (AQ_t 0.59 / AQ_t-1 0.60) |
| SGI: 1.08 (Revenue 407.90b / 378.96b) |
| TATA: -0.03 (NI 2.93b - CFO 10.33b) / TA 252.97b) |
| Beneish M-Score: -3.03 (Cap -4..+1) = AA |
What is the price of CVS shares?
As of May 20, 2026, the stock is trading at USD 94.18 with a total of 12,934,351 shares traded.
Over the past week, the price has changed by -1.02%, over one month by +24.06%, over three months by +22.87% and over the past year by +55.50%.
Over the past week, the price has changed by -1.02%, over one month by +24.06%, over three months by +22.87% and over the past year by +55.50%.
Is CVS a buy, sell or hold?
CVS Health has received a consensus analysts rating of 4.21.
Therefore, it is recommended to buy CVS.
- StrongBuy: 13
- Buy: 8
- Hold: 7
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CVS price?
| Analysts Target Price | 101.6 | 7.9% |
CVS Health (CVS) - Fundamental Data Overview
as of 19 May 2026
P/E Trailing = 42.057 P/E Forward = 12.7389
P/S = 0.3016
P/B = 1.4916
P/EG = 0.2642
Revenue TTM = 407.90b USD
EBIT TTM = 6.57b USD
EBITDA TTM = 11.13b USD
Long Term Debt = 60.53b USD (from longTermDebt, last quarter)
Short Term Debt = 4.48b USD (from shortTermDebt, last quarter)
Debt = 78.34b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 68.80b USD (from netDebt column, last quarter)
Enterprise Value = 188.89b USD (122.35b + Debt 78.34b - CCE 11.80b)
Interest Coverage Ratio = 2.11 (Ebit TTM 6.57b / Interest Expense TTM 3.11b)
EV/FCF = 25.55x (Enterprise Value 188.89b / FCF TTM 7.39b)
FCF Yield = 3.91% (FCF TTM 7.39b / Enterprise Value 188.89b)
FCF Margin = 1.81% (FCF TTM 7.39b / Revenue TTM 407.90b)
Net Margin = 0.72% (Net Income TTM 2.93b / Revenue TTM 407.90b)
Gross Margin = 13.87% ((Revenue TTM 407.90b - Cost of Revenue TTM 351.31b) / Revenue TTM)
Gross Margin QoQ = 15.56% (prev 12.84%)
Tobins Q-Ratio = 0.75 (Enterprise Value 188.89b / Total Assets 252.97b)
Interest Expense / Debt = 0.99% (Interest Expense 774.0m / Debt 78.34b)
Taxrate = 25.27% (995.0m / 3.94b)
NOPAT = 4.91b (EBIT 6.57b * (1 - 25.27%))
Current Ratio = 0.87 (Total Current Assets 74.82b / Total Current Liabilities 86.41b)
Debt / Equity = 1.01 (Debt 78.34b / totalStockholderEquity, last quarter 77.46b)
Debt / EBITDA = 6.18 (Net Debt 68.80b / EBITDA 11.13b)
Debt / FCF = 9.31 (Net Debt 68.80b / FCF TTM 7.39b)
Total Stockholder Equity = 75.74b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.15% (Net Income 2.93b / Total Assets 252.97b)
RoE = 3.87% (Net Income TTM 2.93b / Total Stockholder Equity 75.74b)
RoCE = 4.82% (EBIT 6.57b / Capital Employed (Equity 75.74b + L.T.Debt 60.53b))
RoIC = 3.49% (NOPAT 4.91b / Invested Capital 140.75b)
WACC = 4.86% (E(122.35b)/V(200.69b) * Re(7.50%) + D(78.34b)/V(200.69b) * Rd(0.99%) * (1-Tc(0.25)))
Discount Rate = 7.50% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (quarterly) Correlation: 35.96 | Cagr: -0.48%
[DCF] Terminal Value 83.64% ; FCFF base≈6.81b ; Y1≈5.40b ; Y5≈3.59b
[DCF] Fair Price = 32.38 (EV 110.12b - Net Debt 68.80b = Equity 41.32b / Shares 1.28b; r=6.0% [WACC]; 5y FCF grow -24.86% → 3.0% )
EPS Correlation: -40.58 | EPS CAGR: 1.84% | SUE: 0.98 | # QB: 0
Revenue Correlation: 95.70 | Revenue CAGR: 6.03% | SUE: 2.93 | # QB: 1
EPS current Quarter (2026-06-30): EPS=1.82 | Chg30d=+1.52% | Revisions=+50% | Analysts=19
EPS next Quarter (2026-09-30): EPS=1.71 | Chg30d=-4.90% | Revisions=-20% | Analysts=19
EPS current Year (2026-12-31): EPS=7.43 | Chg30d=+3.78% | Revisions=+65% | GrowthEPS=+10.1% | GrowthRev=+1.8%
EPS next Year (2027-12-31): EPS=8.36 | Chg30d=+2.16% | Revisions=+83% | GrowthEPS=+12.5% | GrowthRev=+4.0%
[Analyst] Revisions Ratio: +83%